Boston Scientific Corporation (BSX) Stock
NYSEBSX has an Alpha Score of 41 out of 100 (weak), computed on Nov 2, 2026 from 3 of 4 sub-scores. 18 members of Congress disclosed 78 trades in BSX since 2015: 35 purchases and 43 sales, most recently Kevin Hern (sale, Sep 9, 2026). 7 of the hedge funds AlphaScala tracks reported BSX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is D.E. Shaw's at $1.09B. Company insiders reported 3 open-market buys and 0 sales on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 17.4 and its net margin 17.5% (key statistics as of Oct 22, 2026).
What is BSX's Alpha Score?
How it works →Alpha Score of 41 reflects weak overall profile with poor momentum, moderate value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 2, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Boston Scientific Corporation (BSX)?
Most recent: Kevin Hern (sale, Sep 9, 2026); records start Mar 18, 2015.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Kevin Hern R-OK · House | 2026-09-09 | sale | $50k – $100k |
| Kevin Hern R-OK · House | 2026-09-04 | partial sale | $50k – $100k |
| Kevin Hern R-OK · House | 2026-09-03 | sale | $1k – $15k |
| Kevin Hern R-OK · House | 2026-08-31 | sale | $15k – $50k |
| Gil Cisneros D-CA · House | 2026-08-18 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-05 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2026-06-05 | partial sale | $1k – $15k |
| John Boozman R-AR · Senate | 2026-06-04 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
Every member of Congress who traded BSX, with filing lags →Which hedge funds own BSX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| D.E. Shaw David Shaw | 25.46M | $1.09B | +5% |
| Maverick Capital Lee Ainslie | 5.94M | $253.41M | +42% |
| Citadel Ken Griffin | 4.99M | $212.88M | +18% |
| Millennium Management Israel Englander | 5.44M | $210.74M | +25% |
| Marshall Wace | 2.41M | $103.04M | -33% |
| Renaissance Technologies Jim Simons (founder) | 2.41M | $102.94M | -23% |
| Bridgewater Associates Ray Dalio | 442K | $18.87M | +474% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Boston Scientific Corporation insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 25, 26 | Morano Susan E | Director | BUY | 2.0K | $100K |
| Aug 5, 26 | Habiger David C | Director | BUY | 2.1K | $100K |
| Aug 4, 26 | Habiger David C | Director | BUY | 140 | $7K |
| Aug 3, 26 | Habiger David C | Director | BUY | 1.0K | $50K |
| Aug 3, 26 | Mahoney Michael F | Chairman, President & CEO | BUY | 186.2K | $9.0M |
| Jul 31, 26 | Ludwig Edward J | Director | BUY | 5.0K | $227K |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are BSX's key statistics?
Key statistics as of Oct 22, 2026
How does BSX's valuation compare with the Healthcare sector?
| Metric | BSX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 17.4 | 27.1 | 97 |
| Net margin | 17.50% | 5.48% | 139 |
| Return on equity | 14.94% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
BSX price chart
Powered by TradingViewWhat does Boston Scientific Corporation do?
Boston Scientific Corporation develops, manufactures, and markets a broad portfolio of medical devices designed for minimally invasive procedures worldwide. The company specializes in innovative technologies that address critical health needs across cardiology, endoscopy, and neuromodulation. Its Cardiovascular segment offers products for angioplasty, stents, cardiac rhythm management, and structural heart interventions, while the MedSurg segment provides solutions for endoscopy, urology, neuromodulation for chronic pain, interventional oncology, and treatments for incontinence and kidney stones. These devices enable healthcare professionals to perform precise diagnostics and therapies with reduced patient recovery times. Boston Scientific Corporation serves physicians, hospitals, and healthcare institutions globally, with a significant portion of sales from international markets. Founded in 1979 and headquartered in Marlborough, Massachusetts, it plays a vital role in advancing interventional medicine and improving patient outcomes in high-volume therapeutic areas.